Corporate Profile
We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see challenges, Amylyx sees opportunities that we pursue with urgency, rigorous science, and unwavering commitment. We explore scientific approaches that are tailored to diseases where we can make the greatest difference, agnostic of modality, in order to usher in a new era of advancements.
Our team brings to Amylyx collective expertise from therapeutic development through commercialization across numerous diseases, which serves as a critical foundation for tackling some of medicine’s toughest challenges.
Today, we are focused on our four investigational therapies across several diseases: avexitide in post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI), AMX0035 in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases.
Minimum 15 minutes delayed. Source: LSEG